Schmith PK

1 Introduction Tourette syndrome (TS) is a chronic neurodevelopmental disorder characterized by motor and vocal tics that can substantially diminish quality of life [1, 2]. Ecopipam (previously referred to as EBS-101 or SCH 39166) is a first-in-class, potent, selective D1 receptor (D1R) antagonist currently in late-stage clinical development for the treatment of TS.

The authors thank Dr. Sellers for his commentary [1] on the drug–drug interaction (DDI) Tutorial [2]. The authors agree, in general, that evaluation of pharmacokinetic DDIs does not explain all DDIs, but pharmacokinetic DDIs significantly improve dosing recommendations for new drugs (Table 1). The authors also agree that standard population studies do not always reflect the true risk or nature of DDIs in specific subgroups.

1 Introduction Tourette syndrome (TS) is a chronic neurodevelopmental disorder characterized by motor and/or vocal tics that can negatively impact quality of life [1, 2]. Ecopipam is a selective dopamine D1 receptor antagonist currently in development for the treatment of TS.